Roche’s lung cancer drug candidate divarasib has beaten marketed drugs from Amgen and Bristol Myers Squibb in a head-to-head trial.

The Phase 3 trial compared Roche’s divarasib with treatments sold by Amgen and Bristol Myers in patients with non-small cell lung cancer.

Swiss pharmaceutical and diagnostics giant Roche announced the success of a pivotal clinical trial for its drug divarasib in the treatment of a form of lung cancer.

(Bloomberg) -- Roche Holding AG’s experimental lung cancer pill outperformed two approved medicines in a late-stage study, boosting the Swiss drugmaker’s bid to bring a…

Roche’s lung cancer drug candidate divarasib has beaten marketed drugs from Amgen and Bristol Myers Squibb in a head-to-head trial.